Erratum: The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways (Cell Death and Differentiation (2006) 10.1038/sj.cdd.4402057);The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways

Cell Death and Differentiation

Volumn 14, Issue 5, 2007, Pages 895-906

  Shapira, S ^a   Barkan, B ^a   Fridman, E ^a,b   Kloog, Y ^a   Stein, R ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROFIBROMIN; RAS PROTEIN; STAUROSPORINE; VINCRISTINE;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG SENSITIVITY; EMBRYO; FIBROBLAST; GENE DOSAGE; HUMAN; HUMAN CELL; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

EID: 34247330161     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4402124     Document Type: Erratum

References (37)

1. Rubin JB, Gutmann DH. Neurofibromatosis type 1 - a model for nervous system tumour formation? Nat Rev Cancer 2005; 5: 557-564.
2. Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ, Haubruck H et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 1990; 63: 843-849.
3. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992; 356: 713-715.
4. DeClue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner N, Vass WC et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 1992; 69: 265-273.
5. Guha A, Lau N, Huvar I, Gutmann D, Provias J, Pawson T et al. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene 1996; 12: 507-513.
6. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 1994; 7: 353-361.
7. Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME et al. Mouse models of tumor development in neurofibromatosis type 1. Science 1999; 286: 2172-2176.
8. Bajenaru ML, Zhu Y, Hedrick NM, Donahoe J, Parada LF, Gutmann DH. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol Cell Biol 2002; 22 5100-5113.
9. Guo HF, Tong J, Hannan F, Luo L, Zhong Y. A neurofibromatosis-1-regulated pathway is required for learning in Drosophila. Nature 2000; 403: 895-898.
10. The I, Hannigan GE, Cowley GS, Reginald S, Zhong Y, Gusella JF et al. Rescue of a Drosophila NF1 mutant phenotype by protein kinase A. Science 1997; 276: 791-794.
11. Johnson MR, DeClue JE, Felzmann S, Vass WC, Xu G, White R et al. Neurofibromin can inhibit Ras-dependent growth by a mechanism independent of its GTPase-accelerating function. Mol Cell Biol 1994; 14: 641-645.
12. Dasgupta B, Dugan LL, Gutmann DH. The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J Neurosci 2003; 23: 8949-8954.
13. Hannan F, Ho I, Tong JJ, Zhu Y, Nurnberg P, Zhong Y. Effect of neurofibromatosis type I mutations on a novel pathway for adenylyl cyclase activation requiring neurofibromin and Ras. Hum Mol Genet 2006; 15: 1087-1098.
14. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991; 352: 345-347.
15. Raveh T, Kimchi A. DAP kinase-a proapoptotic gene that functions as a tumor suppressor. Exp Cell Res 2001; 264: 185-192.
16. Dee K, Freer M, Mei Y, Weyman CM. Apoptosis coincident with the differentiation of skeletal myoblasts is delayed by caspase 3 inhibition and abrogated by MEK-independent constitutive Ras signaling. Cell Death Differ 2002; 9: 209-218.
17. Guerrero S, Casanova I, Farre L, Mazo A, Capella G, Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 2000; 60: 6750-6756.
18. Cox AD, Der CJ. The dark side of Ras: Regulation of apoptosis. Oncogene 2003; 22: 8999-9006.
19. Donovan S, See W, Bonifas J, Stokoe D, Shannon KM. Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells. Cancer Cell 2002; 2: 507-514.
20. Hiatt K, Ingram DA, Huddleston H, Spandau DF, Kapur R, Clapp DW. Loss of the nf1 tumor suppressor gene decreases fas antigen expression in myeloid cells. Am J Pathol 2004; 164: 1471-1479.
21. Klesse LJ, Parada LF. p21 ras and phosphatidylinositol-3 kinase are required for survival of wild-type and NF1 mutant sensory neurons. J Neurosci 1998; 18: 10420-10428.
22. Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, Reid SW et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 1994; 8: 1019-1029.
23. Cichowski K, Santiago S, Jardim M, Johnson BW, Jacks T. Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. Genes Dev 2003; 17: 449-454.
24. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 2005; 102: 8573-8578.
25. Kloog Y, Cox AD. Prenyl-binding domains: Potential targets for Ras inhibitors and anti-cancer drugs. Semin Cancer Biol 2004; 14 253-261.
26. Kloog Y, Cox AD, Sinensky M. Concepts in Ras-directed therapy. Exp Opin Invest Drugs 1999; 8: 2121-2140.
27. Barkan B, Starinsky S, Friedman E, Stein R, Kloog Y. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosistype 1. Clin Cancer Res 2006; 12: 5533-5542.
28. Blum R, Nakdimon I, Goldberg L, Elkon R, Shamir R, Rechavi G et al. E2F1 identified by promoter and biochemical analysis as a central target of glioblastoma cell-cycle arrest in response to Ras inhibition. Int J Cancer 2006; 119: 527-538.
29. Dasgupta B, Gutmann DH. Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo. J Neurosci 2005; 25: 5584-5594.
30. Jondal M, Xue Y, McConkey DJ, Okret S. Thymocyte apoptosis by glucocorticoids and cAMP. Curr Top Microbiol Immunol 1995; 200 67-79.
31. Rosenbaum T, Boissy YL, Kombrinck K, Brannan CI, Jenkins NA, Copeland NG et al. Neurofibromin-deficient fibroblasts fail to form perineurium in vitro. Development 1995; 121: 3583-3592.
32. Schulze KM, Hanemann CO, Muller HW, Hanenberg H. Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis. Hum Mol Genet 2002; 11: 69-76.
33. Hamaratoglu F, Willecke M, Kango-Singh M, Nolo R, Hyun E, Tao C et al. The tumour-suppressor genes NF2/Merlin and expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol 2006; 8: 27-36.
34. Marom M, Haklai R, Ben Baruch G, Marciano D, Egozi Y, Kloog Y. Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid. J Biol Chem 1995; 270: 22263-22270.
35. Lindenboim L, Yuan J, Stein R. Bcl-xS and Bax induce different apoptotic pathways in PC12 cells. Oncogene 2000; 19: 1783-1793.
36. Paz A, Haklai R, Elad G, Ballan E, Kloog Y. Galectin-1 binds H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 2001; 20: 7486-7493.
37. Lindenboim L, Haviv R, Stein R. Inhibition of drug-induced apoptosis by survival factors in PC12 cells. J Neurochem 1995; 64: 1054-1063